Temozolomide

證據等級: L5

預測適應症: 2 個

Temozolomide: From Malignant Glioma to Adult Astrocytic Tumour

One-Sentence Summary

Temozolomide (TMZ) is an oral imidazotetrazine DNA alkylating agent that has become the global standard of care for glioblastoma and anaplastic astrocytoma since the landmark Stupp et al. (2005) Phase 3 trial. The TxGNN model predicts it may be effective for Adult Astrocytic Tumour, with 2 clinical trials and 20 publications currently supporting this direction. This prediction closely aligns with the drug’s well-established global clinical evidence base, making it one of the strongest validation cases in the TxGNN pipeline.

Quick Overview

Item	Content
Original Indication	Not registered in Taiwan; globally approved for Glioblastoma and Anaplastic Astrocytoma
Predicted New Indication	Adult Astrocytic Tumour
TxGNN Prediction Score	99.36%
Evidence Level	L1
US Market Status	✗ Not Marketed (no records in current regulatory dataset)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Temozolomide is an imidazotetrazine-class DNA alkylating agent. Under physiological pH, it spontaneously hydrolyzes to the active metabolite MTIC (5-(3-methyltriazen-1-yl)imidazole-4-carboxamide), which methylates DNA at three key positions: O6-guanine (~5%), N7-guanine (~70%), and N3-adenine (~9%). The O6 methylation lesions trigger the mismatch repair (MMR) system to generate DNA double-strand breaks, ultimately inducing G2/M cell cycle arrest and apoptosis. MGMT (O6-methylguanine-DNA methyltransferase) is the primary resistance mechanism; tumors with MGMT promoter methylation demonstrate significantly enhanced response to TMZ.

Adult astrocytic tumours—including glioblastoma (WHO Grade 4) and anaplastic astrocytoma (WHO Grade 3)—are rapidly dividing, infiltrative CNS malignancies with high susceptibility to DNA alkylating agents. TMZ’s favorable pharmacokinetic profile (lipophilicity LogP ~0.9, molecular weight 194 Da) allows effective penetration of the blood-brain barrier, achieving CSF exposure approximately 30–40% of plasma levels. This CNS penetration is a critical pharmacological advantage that most conventional chemotherapy agents lack.

The biological rationale is substantiated by decades of high-quality clinical evidence. The 2005 EORTC-NCIC Phase 3 trial established TMZ concurrent with and adjuvant to radiotherapy as the global standard of care for newly diagnosed glioblastoma, improving median overall survival from 12.1 to 14.6 months and 2-year survival from 10.4% to 26.5%. Subsequent studies have confirmed its role in MGMT-methylated elderly patients (NOA-08), in combination with tumor-treating fields (EF-14), and in MGMT-methylated patients when combined with lomustine (CeTeG/NOA-09). The TxGNN prediction is therefore a textbook validation of an established indication, underscoring the model’s predictive validity.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00052455	Phase 3	Completed	500	Head-to-head RCT comparing TMZ monotherapy vs. PCV (procarbazine + lomustine + vincristine) in recurrent WHO Grade III–IV astrocytic tumours; large-sample, fully powered comparison establishing TMZ as the preferred chemotherapy in this setting
NCT00960492	Phase 1	Completed	26	Dose-finding study of XL184 (MET/VEGFR2 inhibitor) combined with TMZ and radiotherapy in newly diagnosed glioblastoma; TMZ used at standard dose as backbone agent; supports tolerability of TMZ in combination regimens

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15758009	2005	RCT (Phase 3)	N Engl J Med	Stupp trial: TMZ + radiotherapy vs. radiotherapy alone in newly diagnosed glioblastoma; mOS 14.6 vs. 12.1 months; 2-year survival 26.5% vs. 10.4%; established current standard of care
19269895	2009	RCT Long-term Follow-up	Lancet Oncol	5-year analysis of EORTC-NCIC trial; confirmed durable survival benefit with TMZ; MGMT promoter methylation identified as the key predictive biomarker for treatment response
26670971	2015	RCT (Phase 3)	JAMA	EF-14 trial: Tumor-treating fields + TMZ vs. TMZ alone in maintenance phase; addition of TTFields improved mOS from 16.0 to 20.9 months, leading to FDA approval of TTFields device
30782343	2019	RCT (Phase 3)	Lancet	CeTeG/NOA-09 trial: lomustine + TMZ vs. TMZ alone in newly diagnosed MGMT-methylated GBM; combination therapy superior in methylated subgroup, demonstrating potential to intensify TMZ-based regimens
22578793	2012	RCT (Phase 3)	Lancet Oncol	NOA-08 trial: dose-dense TMZ vs. radiotherapy alone in elderly patients (≥65) with malignant astrocytoma; established TMZ as primary treatment option for MGMT-methylated elderly patients who cannot tolerate full RT
24552317	2014	RCT (Phase 3)	N Engl J Med	Adding bevacizumab to TMZ + radiotherapy did not improve OS in newly diagnosed GBM despite PFS improvement; confirmed TMZ + RT as the non-negotiable standard backbone
25920709	2015	RCT / Phase 3	J Neurooncol	TMZ-based concurrent chemoradiotherapy in anaplastic astrocytoma (AA) and anaplastic oligo-astrocytoma (AOA); extended evidence of TMZ efficacy beyond GBM to lower-grade astrocytic tumours
40779733	2025	RCT (Phase 3)	J Clin Oncol	NRG Oncology BN007: dual immune checkpoint blockade (ipilimumab + nivolumab) with TMZ in MGMT-unmethylated newly diagnosed GBM; TMZ remains the standard chemotherapy backbone in novel combination strategies
36809318	2023	Systematic Review	JAMA	Comprehensive review of primary malignant brain tumors in adults; summarizes TMZ role in standard of care, MGMT biomarker utility, incidence trends, and emerging therapeutic approaches
10914698	2000	Review	Clin Cancer Res	Foundational overview of TMZ mechanism, pharmacokinetics, and early Phase 2 clinical data in malignant glioma; documents initial proof-of-concept for CNS activity and oral bioavailability

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Alkylating agent — Imidazotetrazine class)
Myelosuppression Risk	Moderate-High — Thrombocytopenia and neutropenia are the dose-limiting toxicities; nadir typically at Days 21–28 of each 28-day cycle; Grade 3/4 thrombocytopenia occurs in ~14% of patients
Emetogenicity Classification	Moderate to High — Prophylactic antiemetics (5-HT3 antagonist ± NK1 antagonist) are strongly recommended
Monitoring Items	CBC with differential (before each cycle and at Day 22), liver function (ALT, AST, bilirubin), renal function (creatinine); MGMT promoter methylation status testing recommended prior to initiation for patient stratification
Handling Protection	Must follow cytotoxic drug handling regulations; capsules should not be opened or crushed; healthcare workers should wear protective gloves when handling; considered hazardous per NIOSH classification

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Temozolomide carries L1-level evidence for adult astrocytic tumours, supported by multiple completed Phase 3 RCTs — including the landmark 2005 Stupp trial published in the New England Journal of Medicine — that established it as the global standard of care for glioblastoma and anaplastic astrocytoma. The TxGNN prediction is strongly validated by existing clinical evidence, representing one of the most credible repurposing signals in the dataset. The primary outstanding gap is the absence of local Taiwan regulatory registration and associated pharmacovigilance documentation.

To proceed, the following is needed:

Taiwan TFDA regulatory registration (NDA submission) for the glioblastoma and anaplastic astrocytoma indications
Local Taiwan package insert review to establish key warnings, contraindications, and DDI profile (classified as Blocking data gap DG001)
MGMT promoter methylation testing infrastructure for patient stratification prior to treatment initiation
Reimbursement pathway evaluation under the Taiwan National Health Insurance (NHI) system
Drug interaction assessment, particularly with antiepileptic agents commonly co-prescribed in brain tumor patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.